Psoriatic Arthritis News

• BSR 2022 Risk Factors for COVID Death Studied in U.K. Arthritis Patients Shielding status was the highest ranked of all the risk factors identified for early mortality from COVID-19.
  Medscape Medical News, May 17, 2022
• CARRA 2022 Prior Authorizations Delay TNF Inhibitors for Children With JIA Many patients newly diagnosed with juvenile idiopathic arthritis (JIA) at one academic center over a year had delays in care due to unnecessary prior authorization denials.
  Medscape Medical News, May 11, 2022
• AAD 2022 Dermatology Residency Focuses on Rural Placement of Graduates The structure of the residency, which involves 3-month–long rotations at rural clinics in Mississippi, is designed to address the shortage of rural-based dermatologists in the United States.
  Medscape Medical News, May 11, 2022
• Alert Upadacitinib Earns FDA Approval for Ankylosing Spondylitis Janus kinase inhibitor offers oral option for patients who have failed treatment.
  FDA Approvals, May 02, 2022
• Hypocaloric Diet Controls Joint Activity in Psoriatic Arthritis A 12-week hypocaloric diet provided suitable control of joint disease activity in patients with psoriatic arthritis, regardless of weight loss, Brazilian researchers found.
  Medscape Medical News, April 14, 2022
• AAD 2022 Apremilast's Effect on CVD Risk Markers Evaluated in Study 'There has been a keen interest in understanding how psoriasis therapies impact cardiovascular risk,' said Joel Gelfand, MD, who presented the findings at the American Academy of Dermatology meeting.
  Medscape Medical News, April 06, 2022
• Trial Gives New Guidance for Choosing Initial PsA Treatment Adding the tumor necrosis factor inhibitor adalimumab to methotrexate because of a lack of efficacy or tolerability produced better results than escalating the methotrexate dose alone.
  Medscape Medical News, March 21, 2022
• CV Risk Biomarkers Tentatively Identified in Psoriatic Disease Troponin I and NT-proBNP levels were linked to cardiovascular risk independently of the Framingham Risk Score.
  Medscape Medical News, March 11, 2022
• Methotrexate Plus Leflunomide Proves Effective for PsA The combination therapy outperformed methotrexate monotherapy as a treatment option for patients with psoriatic arthritis (PsA), though it did come with an increase in side effects.
  Medscape Medical News, March 08, 2022
• Analysis: How Common Is Metabolic Syndrome in Patients With PsA? Assessing the prevalence of metabolic syndrome in patients with PsA remains a challenge because the definition varies across studies, according to the authors.
  Medscape Medical News, March 07, 2022
• RWCS 2022 Health Disparities Exist Across Rheumatology: What Can Be Done? Health equity for patients who experience health disparities needs to be a "continuous effort" focusing on the "how" of eliminating disparities rather than checking a box, said Dr Alvin Wells.
  Medscape Medical News, February 28, 2022
• EULAR CVD Management Guidance Focuses on Gout, Lupus, Vasculitis The recommendations advise on managing cardiovascular health in patients with gout, vasculitis, systemic sclerosis, myositis, Sjögren syndrome, lupus, antiphospholipid syndrome, and other diseases.
  Medscape Medical News, February 24, 2022
• RWCS 2022 Patients Interrupting DMARD Use Well Into the COVID-19 Pandemic Rates of patients stopping disease-modifying antirheumatic drugs (DMARDs) have begun to rise after initially falling during the pandemic, with consequent rises in the incidence of disease flares.
  Medscape Medical News, February 17, 2022
• Ustekinumab Has Comparatively Low Infection Rate in IBD The biologic was associated with reduced infection risk when compared with anti-TNF agents or tofacitinib in a real-world analysis of nearly 90 million patients.
  Medscape Medical News, February 11, 2022
• CRA 2022 Guselkumab Controls Axial Involvement in PsA Through 2 Years In psoriatic arthritis patients with axial involvement, researchers saw sustained improvement with guselkumab through 100 weeks on all outcomes employed to evaluate change in axial symptoms.
  Medscape Medical News, February 10, 2022
• Dietary Recommendations for Inflammatory Rheumatic Diseases France's first set of dietary recommendations for chronic inflammatory rheumatic diseases are a welcome guide for healthcare professionals and patients.
  Medscape Medical News, February 09, 2022
• Alert FDA Approves Risankizumab (Skyrizi) for Psoriatic Arthritis The approval is the second indication for the anti-interleukin 23 monoclonal antibody after approval for plaque psoriasis was granted in 2019.
  News Alerts, January 21, 2022
• Risankizumab Effective Against Refractory Psoriatic Arthritis The IL-23 inhibitor provides some relief for patients with active psoriatic arthritis whose symptoms have responded poorly to standard treatments, according to 24-week results of a phase 3 trial.
  Reuters Health Information, January 17, 2022
• Case Series Show No Consensus on Treatment for Palmoplantar Pustulosis, Generalized Pustular Psoriasis "These case series confirm the rarity of both generalized pustular psoriasis and palmoplantar pustulosis...and the lack of effective treatment options," the lead author said.
  Medscape Medical News, January 04, 2022
• Alert FDA Approves Secukinumab (Cosentyx) for Pediatric Arthritis The US Food and Drug administration has approved secukinumab (Cosentyx) for the treatment of children and adolescents for both ERA (4 years of age and older) and PsA (2 years and older) in the US.
  FDA Approvals, December 23, 2021